Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Benzinga's Top Upgrades
The Market In 5 Minutes: Earnings Season Is Upon Us
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued (GuruFocus)
Related NVS
Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
Earnings Scheduled For July 19, 2016
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued (GuruFocus)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

View Comments and Join the Discussion!